Most researchers searching for CJC-1295 in Forcé immediately realize that local retail options are nearly impossible to find. The key implication for Forcé researchers: sourcing CJC-1295 hinges on vendor quality evaluation, not geography — and the quality verification approach is identical for researchers everywhere. Vendors worth sourcing from make readily available batch-matched Certificates of Analysis documenting HPLC purity data, mass spec identity confirmation, endotoxin levels, and residual solvent results — all for the specific lot you are purchasing. This guide gives Forcé researchers the methodology to evaluate CJC-1295 vendors systematically and source high-purity CJC-1295 with confidence.
How CJC-1295 Works — Mechanisms & Research
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Forcé researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
Sourcing Research-Grade CJC-1295
Before evaluating any specific vendor, establish a quality benchmark — so you can recognise whether a vendor meets it. Endotoxin testing in the COA is critical for any injectable research use — endotoxins from microbial contamination can trigger dangerous inflammatory cascades even at minute levels. The combination of community reputation data and your own COA analysis is the most reliable sourcing approach — community feedback surfaces patterns individual COA review misses, and vice versa. The dry lyophilised powder of CJC-1295 is far superior to liquid pre-made solutions — lyophilised powder retains potency for years in frozen storage, while liquid preparations break down rapidly even under refrigeration.
Order CJC-1295 — ships to Forcé
COA-verified · International tracking · Research grade
All use of CJC-1295 in Forcé or anywhere must be research use only — this compound is not approved for human therapeutic use, and all handling should comply with standard research safety practices. Reconstitute CJC-1295 with bacteriostatic water at the concentration suited to your research design; a standard 5mg reconstituted in 2mL produces 2.5mg/mL — equivalent to 25mcg per unit on an insulin syringe. Endotoxin testing in the CJC-1295 COA is not optional — gram-negative bacterial endotoxins can trigger dangerous immune responses at minute levels, and no cost saving makes omitting this acceptable. For any individual considering CJC-1295 outside a formal research context: seek medical advice first — this compound is unapproved for human therapeutic application and its safety characterisation does not match that of regulated drugs.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
